We analyzed the tPA content in primary gastric carcinomas and surrounding mucosa in order to assess the relationship between tPA content, clinicopathological tumor characteristics, and estrogen and progesterone receptor content. We evaluated the prognostic value of this serine protease in gastric cancer patients.
Patients and methods
122 resected gastric neoplasms and 95 adjacent mucosa samples were studied. The tPA content was measured in cytosol by an ELISA method. Cytosolic ER and PgR were measured with a solid phase enzyme immunoassay.
Results
Cytosolic tPA levels in neoplastic tissues (median 1.0 ng/mg prot) were significantly lower (p=0.002) than those found in paired mucosa samples (median 2.3 ng/mg prot). There was no significant association between tPA levels and clinicopathological parameters or PgR content, but tPA levels were significantly correlated with ER content. The intermediate-tPA-content group, corresponding to samples with between 0.3 and 1.70 ng/mg protein, proved to have a significantly high risk of relapse.
Conclusions
We found a wide variability in tPA levels in gastric carcinoma and adjacent mucosa samples, with significantly decreased levels in tumors and a significantly positive relationship between tPA levels and ER status. There was a non-monotonic relationship between tPA levels and prognosis in patients with gastric cancer.
DanoK., AndreasenP.A., Grondahl-HansenJ., KristensenP., NielsenL.S., SkriverL.Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res1985; 44: 139–266.
3.
MignattiP., RifkinD.B.Biology and biochemistry of proteinases in tumor invasion. Physiol Rev1993; 73: 161–95.
4.
LiottaL.A., ThorgeirssonU.P., GarbisaS.Role of collagenases in tumor cell invasion, tissue degradation, and cancer. Cancer Metastasis Rev1982; 1: 277–97.
5.
SierC.F.M., VerspagetH.W., GriffioenG.Imbalance of plasminogen activators and their inhibitors in human colorectal neoplasia. Implication of urokinase in colorectal carcinogenesis. Gastroenterol1991; 101: 1522–8.
6.
TanakaN., FukaoH., UeshimaS., OkadaK., YasutomiM., MatsuoO.Plasminogen activator inhibitor in human carcinoma tissues. Int J Cancer1991; 48: 481–4.
7.
NakamuraM., KonnoH., TanakaT.Possible role of plasminogen activator inhibitor 2 in the prevention of the metastasis of gastric cancer tissues. Throm Res1992; 65: 709–19.
8.
De VriesT.J., QuaxP.H.A., DenijnM.Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progression. Am J Pathol1994; 144: 70–81.
9.
FoekensJ.A., SchmittM., van PuttenW.L.J.Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res1992; 52: 6101–5.
10.
De WitteJ.H., SweepC.G.J., KlijnJ.G.M.Prognostic value of tissue-type plasminogen activator (tPA) and its complex with type-1 inhibitor (PAI-1) in breast cancer. Br J Cancer1999; 80: 286–94.
11.
JahkolaT., ToivonenT., von SmittenK., VirtanenI., WaseniusV-M, BiomqvistC.Cathepsin D, urokinase plasminogen activator and type-1 plasminogen activator inhibitor in early breast cancer: an immunohistochemical study of prognostic value and relations to tenascin-C and other factors. Br J Cancer1999; 80: 167–74.
12.
PedersenH., BrunnerN., FrancisD.Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res1994; 54: 4671–5.
13.
HasuiY., MarutsukaK., SuzumiyaJ., KitadaS., OsadaY., SumiyoshiA.The content of urokinase-type plasminogen activator antigen as a prognostic factor in urinary bladder cancer. Int J Cancer1992; 50: 871–3.
14.
DuffyM.J., O'GradyP., SimonJ., RoseM., LijnenH.R.Tissue-type plasminogen activator in breast cancer: relationship with estradiol and progesterone receptors. J Natl Cancer Inst1986; 77: 621–3.
15.
JänickeF., SchmittM., GraeffH.Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type-1 inhibitor in breast cancer. Sem Thromb Hemost1991; 17: 303–12.
16.
De WitteJ.H., SweepC.G.J., KlijnJ.G.M.Prognostic impact of urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) in cytosols and pellet extracts derived from 892 breast cancer patients. Br J Cancer1999; 79: 1190–8.
17.
FarinatiF., HersenyiL., PlebaniM.Increased levels of cathepsin B and L, urokinase-type plasminogen activator and its inhibitor type-1 as an early event in gastric carcinogenesis. Carcinogenesis1996; 17: 2581–7.
18.
KawasakiK., HayashiY., WangY.Expression of urokinase-type plasminogen activator receptor and plasminogen activator inhibitor-1 in gastric cancer. J Gastroenterol Hepatol1998; 13: 936–44.
19.
OkusaY., IchikuraT., MochizukiH., ShinomiyaN.Urokinase type plasminogen activator and its receptor regulate the invasive potential of gastric cancer cell lines. Int J Oncol2000; 17: 1001–5.
20.
GaneshS., SierC.F., HeerdingM.M.Prognostic value of the plasminogen activation system in patients with gastric carcinoma. Cancer1996; 77: 1035–43.
21.
OkusaY., IchikuraT., MochizukiH.Prognostic impact of stromal cell-derived urokinase-type plasminogen activator in gastric carcinoma. Cancer1999; 85: 1033–8.
22.
UmeharaY., KimuraT., YoshidaM., ObaN., HaradaY.Relationship between plasminogen activators and stomach carcinoma stage. Acta Oncol1991; 30: 815–8.
LaurenP.The two histological main types of gastric carcinoma: diffuse and so-called intestinal type carcinomas. An attempt at a histological classification. Acta Pathol Microbiol Scand1965; 64: 31–49.
25.
BradfordM.M.A rapid and sensitive method for the quantitation of microgram quantites of protein utilizing the principle of protein-dye binding. Anal Biochem1976; 72: 248–54.
26.
SanzL., RodríguezJ.C., SuárezC.Estrogen and progesterone receptor content in gastric cancer: relationship with clinico-pathologic parameters and prognostic significance. Int J Surg Invest2001; 3: 361–8.
RaigosoP., JuncoA., AndicoecheaA.Tissue-type plasminogen activator (tPA) content in colorectal cancer and in surrounding mucosa: relationship with clinicopathologic parameters and prognostic significance. Int J Biol Markers2000; 15: 44–50.
29.
NeedhamG.K., SherbetG.V., FarndonJ.R., HarrisA.L.Binding of urokinase to specific receptor sites on human breast cancer membranes. Br J Cancer1987; 55: 13–6.
30.
SchmittM., JanickeF., GraeffH.Tumour-associated fibrinolysis: the prognostic relevance of plasminogen activators uPA and tPA in human breast cancer. Blood Coagul Fibrinolysis1990; 1: 695–702.
31.
RellaC., CovielloM., QuarantanaM., ParadisoA.Tissue-type plasminogen activator as a marker of functional steroid receptors in human cancer. Thromb Res1993; 69: 209–20.
32.
ButlerW.B., KirklandW.L., GargalaT.L., GoranN., KelseyW.H., BerlinskyP.J.Steroid stimulation of plasminogen activator production in a human breast cancer cell line (MCF-7). Cancer Res1983; 43: 1637–41.
33.
Mira-Y-LopezR., OssowskiL.Hormonal modulation of plasminogen activator; an approach to predicting human breast tumor responsiveness. Cancer Res1987; 47: 3558–64.
34.
SicaV., NolaE., ContieriE.Estradiol and progesterone receptors in malignant gastrointestinal tumours. Cancer Res1984; 44: 4670–4.
35.
TokunagaA., NishiK., MatsukuraN.Estrogen and progesterone receptors in gastric cancer. Cancer1986; 56: 1376–9.
36.
KaratD., BrotherickI., ShentonB.K., ScottD., RaimesS.A., GriffinS.M.Expression of estrogen and progesterone receptors in gastric cancer: a flow cytometric study. Br J Cancer1999; 80: 1271–4.
37.
OshimaC.T., WonrahtD.R., CatarinoR.M., MattosD., ForonesN.M.Estrogen and progesterone receptors in gastric cancer and colorectal cancer. Hepato-Gastroenterology1999; 46: 3155–8.
38.
MessaC., PricciM., LinsalataM., RussoF., Di LeoA.Inhibitory effect of 17ß-estradiol on growth and the polyamine metabolism of human gastric carcinoma cell line (HGC-27). Scand J Gastroenterol1999; 34: 79–84.
39.
MessaC., RussoF., PricciM., Di LeoA.Epidermal growth factor and 17ß-estradiol effects on proliferation of a human gastric cancer cell line (AGS). Scand J Gastroenterol2000; 35: 753–8.
40.
GaneshS., SierC.F.M., GriffioenG.Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer. Cancer Res1994; 54: 4065–71.
41.
GaneshS., SierC.F.M., HeerdingM.M.Contribution of plasminogen activators and their inhibitors to the survival prognosis of patients with Dukes’ stage B and C colorectal cancer. Br J Cancer1997; 75: 1793–801.
42.
VerspagetH.W., SierC.F.M., GaneshS., GriffioenG., LamersCBHM. Prognostic value of plasminogen activators and their inhibitors in colorectal cancer. Eur J Cancer1995; 31A: 1105–9.
